Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Jun 19, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how low anterior resection surgery affects the quality of life for women with advanced ovarian cancer. The main goal is to find out how often patients experience low anterior resection syndrome, which can cause issues with bowel function after surgery. The trial is currently looking for women aged 18 and older who have been newly diagnosed with ovarian cancer or related conditions and are planning to have a specific type of surgery after chemotherapy.
To be eligible for this study, participants should have certain types of advanced ovarian cancer and be in good overall health, meaning they can perform daily activities without too much difficulty. However, women who have had similar surgeries in the past or specific other medical conditions may not qualify. If you decide to participate, you can expect to share your experiences after surgery to help researchers understand the impact on your everyday life. This information is important for improving care for future patients with similar diagnoses.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Those with newly diagnosed ovarian cancer, fallopian tube cancer and primary peritoneal carcinomatosis who plan to undergo cytoreductive surgery and secondary cytoreductive surgery after neoadjuvant chemotherapy.
- • Patients with PCDS or rectal and sigmoid coloni tumor invasion suspected on the preoperative image and need resection of the tumor and clinical FIGO stage IIIB or higher
- • ECOG performance status : 0-2
- • Age over 18
- Exclusion Criteria:
- • Patient who underwent low anterior resection in the past
- • Past history of gastrointestinal malignant tumor except to ovarian cancer
- • Patient who have colostomy
- • Patient who underwent radiation therapy to abdominal or pelvic cavity
- • ECOG performance status over 3
- • Patient taking opioid analgesics
- • Patient who have intellectual disability or dementia
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Hee Seung Kim, MD/PhD
Principal Investigator
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials